{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"417","value":"13.0"},{"groupId":"OG001","lowerLimit":"4","upperLimit":"1008","value":"10.0"},{"groupId":"OG002","lowerLimit":"12","upperLimit":"112","value":"21.0"},{"groupId":"OG003","lowerLimit":"14","upperLimit":"176","value":"20.5"},{"groupId":"OG004","lowerLimit":"14","upperLimit":"168","value":"28.0"},{"groupId":"OG005","lowerLimit":"11","upperLimit":"57","value":"24.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"15"}],"units":"Participants"}],"title":"Hematologic Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56","upperLimit":"343","value":"85.0"},{"groupId":"OG001","lowerLimit":"49","upperLimit":"333","value":"84.0"},{"groupId":"OG002","lowerLimit":"26","upperLimit":"280","value":"113.5"},{"groupId":"OG003","lowerLimit":"25","upperLimit":"295","value":"83.0"},{"groupId":"OG004","lowerLimit":"28","upperLimit":"168","value":"28.0"},{"groupId":"OG005","lowerLimit":"27","upperLimit":"112","value":"56.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"16"}],"units":"Participants"}],"title":"Cytogenetic Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55","upperLimit":"1686","value":"173.0"},{"groupId":"OG001","lowerLimit":"81","upperLimit":"756","value":"167.0"},{"groupId":"OG002","lowerLimit":"55","upperLimit":"1364","value":"340.5"},{"groupId":"OG003","lowerLimit":"107","upperLimit":"925","value":"335.5"},{"groupId":"OG004","lowerLimit":"54","upperLimit":"113","value":"56.0"},{"groupId":"OG005","lowerLimit":"59","upperLimit":"67","value":"63.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"title":"Molecular Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"65"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"48"},{"groupId":"OG005","value":"46"}],"units":"Participants"}],"description":"Time to response is defined as the interval from the first dose of study treatment until the criteria for response are first met, censored at the last assessment of response. Median time to response was estimated using the Kaplan-Meier method.","dispersionType":"Full Range","groups":[{"description":"CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG000","title":"Cohort A: CP-CML R-I"},{"description":"CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG001","title":"Cohort B: CP-CML With T315I Mutation"},{"description":"AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG002","title":"Cohort C: AP-CML R-I"},{"description":"AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG003","title":"Cohort D: AP-CML With T315I Mutation"},{"description":"BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG004","title":"Cohort E: BP-CML/Ph+ ALL R-I"},{"description":"BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG005","title":"Cohort F: BP-CML or Ph+ ALL With T315I Mutation"}],"paramType":"MEDIAN","populationDescription":"Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. Median time to response was reported for responders only. Participants who did not achieve the specified response were censored at the last response assessment. Number analyzed: participants with data available at given time-point.","reportingStatus":"POSTED","timeFrame":"Up to approximately 48 months after first dose","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"days"}